COMMUNIQUÉS West-GlobeNewswire

Paratek Pharmaceuticals to Report Second Quarter 2018 Financial Results on August 2, 2018
23/07/2018
BOSTON, July 23, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline [...]
RedHill Biopharma Announces Uplisting to Nasdaq Global Market
23/07/2018
TEL-AVIV, Israel and RALEIGH, N.C., July 23, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily [...]
Midatech Pharma US announces Co-Promotion Agreement with Bausch Health Companies Inc. for the Exclusive Right to Promote NeutraSal® to the Oncology Market in United States
23/07/2018
23 July 2018 Midatech Pharma PLC (“Midatech”, “Company” or “Group”) Midatech Pharma US announces Co-Promotion Agreement with Bausch Health Companies Inc. for the Exclusive Right to Promote NeutraSal® to the Oncology [...]
Helius Medical Technologies, Inc. Announces Results of Matters Submitted for Vote at 2018 Annual Shareholder Meeting
23/07/2018
NEWTOWN, Pa., July 23, 2018 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (TSX:HSM) (Nasdaq:HSDT) (“ Helius ” or the “ Company ”) announced today the results of the matters submitted for voting at the annual [...]
AGTC Treats First Patient of Second Cohort in Phase 1/2 Clinical XLRP Study; Earns $10 Million Enrollment Milestone
23/07/2018
Company Provides Pipeline Enrollment Update for Clinical Trials in Inherited Retinal Diseases GAINESVILLE, Fla. and CAMBRIDGE, Mass., July 23, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ: [...]
Arcturus Therapeutics Achieves Program Milestones and Refines Agreement with Cystic Fibrosis Foundation Therapeutics
23/07/2018
SAN DIEGO, July 23, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, today announced the achievement of key milestones as part of its agreement with Cystic Fibrosis [...]
Epizyme Appoints Dr. Shefali Agarwal as Chief Medical Officer
23/07/2018
CAMBRIDGE, Mass., July 23, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, today announced the appointment of Dr. Shefali Agarwal as chief medical [...]
Agios to Webcast Conference Call of Second Quarter 2018 Financial Results on August 2, 2018
23/07/2018
CAMBRIDGE, Mass., July 23, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company [...]
Intra-Cellular Therapies Announces Publication Highlighting ITI-214 Mechanism of Action and Describing Positive Results in Preclinical Models of Heart Failure
23/07/2018
Data indicates ITI-214 acts by a novel mechanism of action via modulation of the adenosine A 2B receptor signaling pathway ITI-214 increases cardiac contractility without increasing intracellular calcium These data may [...]
Auxly Announces Issuance of Sales Licence for Kolab Project and Provides Update on Saskatchewan Retail Strategy
23/07/2018
VANCOUVER, British Columbia, July 23, 2018 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX.V:XLY) (" Auxly " or the " Company ") is pleased to announce that its wholly-owned subsidiary, Kolab Project Inc. (" Kolab " [...]
Reata Announces Positive Phase 2 Data for Bardoxolone Methyl in CKD Caused by Alport Syndrome and Autosomal Dominant Polycystic Kidney Disease
23/07/2018
Statistically Significant Improvement in Kidney Function Maintained in Alport Syndrome Patients After 48 Weeks of Treatment Statistically Significant Retained Benefit of 4.1 mL/min in Alport Syndrome Patients Following [...]
Cambrex to Acquire Halo Pharma, Adding Drug Development and Finished Dosage Capabilities to Global API Manufacturing Network
23/07/2018
-- Conference Call at 8:30 a.m. ET Today -- EAST RUTHERFORD, N.J., July 23, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical [...]
HEXO Reaches Major Milestone in Ongoing Expansion Plans
23/07/2018
GATINEAU, Quebec, July 23, 2018 (GLOBE NEWSWIRE) -- The Hydropothecary Corporation (“HEXO” or the “Company”) (TSX:HEXO) has reached a major milestone in its expansion plans, designed to position HEXO as one of the [...]
HEXO franchit une étape importante dans ses plans d'expansion en cours
23/07/2018
GATINEAU, Québec, 23 juill. 2018 (GLOBE NEWSWIRE) -- La Société Hydropothecary (« HEXO » ou « la Société ») (TSX:HEXO) a franchi une étape importante dans ses plans d'expansion visant à positionner HEXO comme l'un des [...]
Sernova Completes Oversubscribed Private Placement of $2,754,000
23/07/2018
LONDON, Ontario, July 23, 2018 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE:PSH) announces it has completed a non-brokered private placement of $2.754 million, pursuant to which Sernova issued a [...]
PotNetwork Holding's Diamond CBD Scores Over $300,000 in Sales at the 38th Las Vegas CHAMPS Show
23/07/2018
The Company Continues Record Breaking Trend, Having Showcased Growing Product line to Vendors at the World’s Most Trusted Counter-Culture Trade Show FT LAUDERDALE, Fla., July 23, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE [...]
Transactions under Novozymes’ stock buyback program
23/07/2018
Please read the full announcement in the attached PDF Attachment 2018_44_Stock_Buybackprogram_EN
Novo Nordisk A/S: Share repurchase programme
23/07/2018
Bagsværd, Denmark, 23 July 2018 - On 4 May 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR [...]
Immunicum AB (publ) Announces Protocol Approval by the FDA Enabling the Initiation of Expanded Multi-indication Phase Ib/II Combination Trial
23/07/2018
Press Release 23 July 2018 Immunicum AB (publ) Announces Protocol Approval by the FDA Enabling the Initiation of Expanded Multi-indication Phase Ib/II Combination Trial Immunicum AB (publ; IMMU.ST) announced today that [...]

Pages